Benefits
Bilirubin clearance: one small 1996 trial in people with viral hepatitis
This is the most studied use of kutki, but the human evidence is a single trial. In a 1996 Indian randomized placebo-controlled study, 33 people with acute viral hepatitis (15 on kutki, 18 on placebo) took 375 mg three times a day for 2 weeks. Serum bilirubin fell to 2.5 mg% in an average of 27.4 days on kutki versus 75.9 days on placebo. That is one small trial from 1996 in people with a diagnosed liver infection, and it says nothing about what kutki does for a healthy person. The rest is animal work: picroliv, a standardized kutki extract, reduced liver damage in rats given acetaminophen, carbon tetrachloride, oxytetracycline, alcohol or aflatoxin. Anyone with liver disease or jaundice needs medical care, not a supplement.
Fatty liver: no human studies, only animal and laboratory work
There is no human study of kutki for fatty liver. The source cited here (Raut 2023) is a review article, not a trial, and it argues that kutki should be researched for fatty liver in future rather than reporting that it worked. The supporting work is in animals, where kutki extracts lowered fat build-up in the liver and improved insulin sensitivity. Fatty liver disease is a medical diagnosis that needs a doctor, and kutki has not been shown to treat it.
Immunomodulation
In animals, picroliv and kutki extracts changed immune measures such as T-cell function, natural killer cell activity and antibody response. All of that is animal and cell work; no study has shown kutki improves immune function in a healthy person. The only human data touching immunity come from a 2024 trial of AEV01, a different proprietary P. kurroa extract, given alongside standard medical care to 70 patients over 50 with mild COVID-19, which reported changes in TNF-alpha, IL-6 and CD4 counts. Nothing in that trial supports using kutki to prevent or treat COVID-19 or any other infection.
Anti-inflammatory effects (animal and laboratory studies)
In laboratory and animal studies, kutki extracts blocked NF-kB signaling and lowered inflammatory messengers such as TNF-alpha, IL-1 beta and prostaglandins, and reduced signs of inflammation in animal models of arthritis, asthma and bowel inflammation. All of that is in animals and cells. No trial has tested whether kutki itself reduces inflammation in people, and it should not be used in place of treatment for arthritis, asthma or bowel disease.
Bile flow (traditional use plus animal data)
Kutki is traditionally classed as a bile-stimulating herb, and animal and laboratory work suggests it increases bile production in the liver rather than squeezing the gallbladder. None of the cited studies measured bile flow in people, and claims about detoxification or blood fats are not supported by human data. What most people will actually notice is the gut effect: kutki is a bitter purgative and commonly loosens stools.
Mechanism of action
Hepatocyte membrane stabilization
In animal and laboratory studies, kutkin/picroliv appears to help liver cell membranes hold up against toxins, which reduces the leak of liver enzymes (ALT, AST) into the blood. Researchers propose that picrosides interact with membrane fats and may affect ion channels. This is a proposed mechanism from animal work, not something demonstrated in people, and the comparison with milk thistle is a laboratory comparison only.
Antioxidant: GSH and CAT/SOD upregulation
In animal studies, kutki extracts raised liver levels of antioxidant defenses such as glutathione, catalase and superoxide dismutase, and lowered a marker of fat oxidation (MDA) in liver tissue. These are measurements taken from animal liver tissue, not from people.
Cholagogic effect via bile acid synthesis
Animal work suggests kutki increases the liver's production of bile acids from cholesterol, which raises bile flow. Whether that lowers cholesterol or helps the body clear anything in humans has not been tested in any study cited on this page.
NF-κB and inflammatory pathway inhibition
In cell and animal studies, kutkin/picroliv damps down NF-kB activity and the inflammatory messengers it drives (TNF-alpha, IL-1 beta, IL-6). Those effects have been seen in animal models of liver inflammation, arthritis and asthma. They have not been confirmed in people.
Clinical trials
Review article, not a clinical trial (Almeleebia TM, Alsayari A, Wahab S, 2022, Molecules 27(23):8316, doi:10.3390/molecules27238316). PubMed classifies this paper as a review, meaning it summarizes other researchers' work and reports no new results in people.
A review of laboratory and animal research on P. kurroa covering liver protection, immune and inflammatory effects, and blood-sugar and cancer-cell experiments. No participants were enrolled, because a review does not test anything in people.
The authors identify kutkin (a mix of kutkoside and picrosides) as the main liver-active compound and note that the liver-protective evidence comes mainly from animal experiments (acetaminophen, carbon tetrachloride and alcohol-induced damage). Traditional use covers viral hepatitis, jaundice and fevers. The review concludes that rigorous human trials with standardized extracts are still needed. It also flags that Picrorhiza kurroa is an endangered plant.
Translational review (Raut A, Dhami-Shah H, Phadke A, Shindikar A, Udipi S, Joshi J, Vaidya R, Vaidya ADB 2023, J Ayurveda Integr Med 14(1):100558, doi:10.1016/j.jaim.2022.100558).
Review of traditional uses, phytopharmacology, and translational potential of P. kurroa specifically for fatty liver disease (NAFLD) therapy.
This is a review article, not a study. It summarizes traditional use and laboratory findings, identifies the iridoid glycosides (picrosides) as the active molecules, and argues that kutki should be developed and properly tested for fatty liver in future research. It reports no human fatty liver trial, and no such trial is cited anywhere on this page.
Pharmacology review (Verma PC, Basu V, Gupta V, Saxena G, Rahman LU 2009, Curr Pharm Biotechnol 10(6):641-649, doi:10.2174/138920109789069314).
Review of picroliv pharmacology and chemistry from roots and rhizomes of P. kurroa.
This is a review article, not a trial. It describes rat experiments in which picroliv (standardized kutkin) reduced oxytetracycline-induced liver damage in a dose-dependent way (1.5-12 mg/kg by mouth for 7 days), and it summarizes proposed mechanisms: liver cell membrane stabilization, antioxidant defenses and increased bile flow. Every efficacy result described here is from animals, not people.